Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · biote Corp. (BTMD)

Biote Q2 revenue falls 9.5% to $44.2 million, net loss of $7.4 million; outlook revised

Negative Impact 4 of 5 earnings Written later

Biote reported second-quarter 2026 revenue of $44.2 million, down 9.5% from $48.9 million a year earlier, and a net loss of $7.4 million, compared with net income of $3.9 million. The company said the January 2026 voluntary product recall drove the decline and revised its full-year 2026 outlook, now calling for revenue above $175 million and Adjusted EBITDA above $25 million, and delaying its expected return to year-over-year procedure revenue growth.

Key points

  • Q2 2026 revenue was $44.2 million, down 9.5%; procedure revenue fell 13.9% to $30.3 million, tied to the voluntary recall initiated in January 2026
  • Net loss was $(7.4) million, or $(0.23) per diluted share, versus net income of $3.9 million, or $0.10 per diluted share, in Q2 2025
  • Adjusted EBITDA was $5.6 million, down from $15.2 million; gross profit margin fell to 65.4% from 71.6%
  • 2026 guidance: revenue above $175 million and Adjusted EBITDA above $25 million; procedure revenue still expected to decline year over year in Q3 and Q4

The filing

Companybiote Corp. (BTMD)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:20 PM ET
Accession number0001193125-26-335200

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.